- |||||||||| Journal: Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma. (Pubmed Central) - Nov 30, 2017
This presents an opportunity to develop miR-181c and NOTCH2 as markers for early identification of high risk cases and the use of NOTCH inhibitors in the prevention or treatment of recurrent disease. Our study suggests that taxane/platinum doublet may be a more effective chemotherapy regimen compared to other regimens among women with recurrent uterine carcinosarcoma, especially for those who had a disease-free interval of ≥6months.
- |||||||||| Review, Journal: Neurofibromatosis Type 1-Associated MPNST State of the Science: Outlining a Research Agenda for the Future. (Pubmed Central) - Nov 30, 2017
Key recommendations included the: 1) development of standardized, cost-efficient fluorodeoxyglucose positron emission tomography and whole-body magnetic resonance imaging guidelines to evaluate masses concerning for MPNST; 2) development of better understanding and histologic criteria for the transformation of a plexiform neurofibroma to MPNST; 3) establishment of a centralized database to collect genetic, genomic, histologic, immunohistochemical, molecular, radiographic, treatment, and related clinical data from MPNST subspecialty centers in a standardized manner; 4) creation of accurate mouse models to study the plexiform neurofibroma-to-MPNST transition, MPNST metastasis, and drug resistance; 5) use of trial designs that minimize regulatory requirements, maximize availability to patients, consider novel secondary end points, and study patients with newly diagnosed disease. Lastly, in order to minimize delays in developing novel therapies and promote the most efficient use of research resources and patient samples, data sharing should be incentivized.
- |||||||||| Sutent (sunitinib) / Pfizer
Trial completion, HEOR, Metastases: Study on the Influence of Sunitinib and Sorafenib on Fatigue, QoL, Depression in Patients With Metastatic RCC or GIST (clinicaltrials.gov) - Nov 28, 2017 P=N/A, N=100, Completed, Lastly, in order to minimize delays in developing novel therapies and promote the most efficient use of research resources and patient samples, data sharing should be incentivized. Active, not recruiting --> Completed
- |||||||||| Trial withdrawal: A Vaccine Study for High Risk Cancers (clinicaltrials.gov) - Nov 24, 2017
P1, N=0, Withdrawn, Suspended --> Active, not recruiting | N=360 --> 28 Terminated --> Withdrawn
- |||||||||| temozolomide / Generic mfg.
Phase classification, Trial primary completion date: Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Nov 22, 2017 P1, N=21, Active, not recruiting, Our collective results demonstrate that Reolysin possesses CXCL10-driven anti-angiogenic activity in sarcoma models, which can be harnessed to enhance the anticancer activity of temsirolimus and other agents that target the tumor vasculature. Phase classification: P=N/A --> P1 | Trial primary completion date: Nov 2017 --> Feb 2017
- |||||||||| Biomarker, Journal: CD49b inhibits osteogenic differentiation and plays an important role in osteosarcoma progression. (Pubmed Central) - Nov 21, 2017
CD49b expression in osteosarcoma patients was associated with presence of metastases and inferior 5 year overall survival (31.4% vs. 57.4%, p=0.03). Surface proteins involved in osteosarcoma cell differentiation, such as CD49b, have the potential to serve as prognostic biomarkers, and may lead to the identification of new therapeutic targets.
- |||||||||| cisplatin / Generic mfg., acetylcysteine solution / Generic mfg.
Trial primary completion date: NAC to Prevent Cisplatin-induced Hearing Loss (clinicaltrials.gov) - Nov 14, 2017 P1, N=30, Recruiting, Trial primary completion date: Dec 2017 --> Jun 2018 Trial primary completion date: Feb 2018 --> Feb 2019
- |||||||||| Votrient (pazopanib) / Novartis
Enrollment change, Trial initiation date, Trial termination, Trial primary completion date: Pazopanib Maintenance Phase II (clinicaltrials.gov) - Nov 13, 2017 P2, N=1, Terminated, N=48 --> 18 N=150 --> 1 | Initiation date: Dec 2014 --> Jun 2015 | Recruiting --> Terminated | Trial primary completion date: Jun 2017 --> Jul 2016; poor recruitment
- |||||||||| Journal: From vision to reality: deploying the immune system for treatment of sarcoma. (Pubmed Central) - Nov 10, 2017
We review the available literature regarding the immune microenvironment in sarcomas, with emphasis on tumor evasion mechanisms that can be targeted with immunotherapeutic strategies. We also highlight recent clinical trials of immunotherapy that show exciting signals of activity in refractory sarcomas.
- |||||||||| Journal: Inhibition of porcupine prolongs metastasis free survival in a mouse xenograft model of Ewing sarcoma. (Pubmed Central) - Nov 9, 2017
The drug produces no survival benefit in a tail vein injection model, supporting the hypothesis that WNT974 inhibits early steps in the metastatic cascade, such as migration and invasion. Our findings strongly implicate Wnt signaling in the early steps of ES metastasis and demonstrate that WNT974 has the potential to significantly improve the survival of ES patients through the specific inhibition of metastasis.
- |||||||||| Journal: Size-based detection of sarcoma circulating tumor cells and cell clusters. (Pubmed Central) - Nov 9, 2017
Although evaluation of CTC is established in the care of patients with carcinomas, this technology has yet to be effectively applied to the evaluation and treatment of sarcoma patients. Our work demonstrates that the CellSieve™ microfiltration system can be used to study the biology of CTC in both mouse models and human sarcoma patients, with the potential for application to the monitoring of disease response and prediction of metastatic relapse.
- |||||||||| Sutent (sunitinib) / Pfizer
Trial primary completion date, Stroma: Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan). (clinicaltrials.gov) - Nov 9, 2017 P=N/A, N=472, Completed, Our work demonstrates that the CellSieve™ microfiltration system can be used to study the biology of CTC in both mouse models and human sarcoma patients, with the potential for application to the monitoring of disease response and prediction of metastatic relapse. Trial primary completion date: May 2013 --> Oct 2015
- |||||||||| Journal: Characterization of 298 lung cancer patients harboring MET exon 14 skipping (METex14) alterations. (Pubmed Central) - Nov 8, 2017
Diverse targetable METex14 alterations were identified in patients with NSCLC across age groups, including elderly patients, and in all major NSCLC histologic subtypes with an overall frequency of 2.7%. These findings support the use of hybrid capture-based molecular profiling across NSCLC subtypes to identify patients who will potentially benefit from MET TKIs.
- |||||||||| Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment open, Trial initiation date, Metastases: NYESO SCT: Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer (clinicaltrials.gov) - Nov 7, 2017 P1, N=12, Recruiting, Trial primary completion date: Mar 2018 --> Mar 2019 Not yet recruiting --> Recruiting | Initiation date: Dec 2017 --> Jul 2017
|